Advertisement

Drugs

pp 1–8 | Cite as

Risankizumab: First Global Approval

  • Kate McKeageEmail author
  • Sean Duggan
AdisInsight Report
  • 22 Downloads

Abstract

Risankizumab (Skyrizi®), a humanised IgG monoclonal antibody that targets the p19 subunit of IL-23, was developed by AbbVie in collaboration with Boehringer Ingelheim for the treatment of immunological and inflammatory disorders. In March 2019, risankizumab received its first global approval in Japan for the treatment of adults with psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis. Risankizumab has also received approval in the USA, Canada and the EU for the treatment of moderate-to-severe plaque psoriasis, and is in phase 3 development for this indication as well as psoriatic arthritis in several countries worldwide. Phase 2 and 3 clinical evaluation of risankizumab is ongoing in several countries in the treatment of Crohn’s disease and ulcerative colitis. Risankizumab is also in phase 2 development for the treatment of atopic dermatitis globally. This article summarizes the milestones in the development of risankizumab leading to this first approval for psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis.

Notes

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Kate McKeage and Sean Duggan are contracted employees of Adis/Springer, are responsible for the article content and declare no relevant conflicts of interest.

References

  1. 1.
    Torres T. Selective interleukin-23 p19 inhibition: another game changer in psoriasis? Focus on risankizumab. Drugs. 2017;77(14):1493–503.CrossRefGoogle Scholar
  2. 2.
    Haugh IM, Preston AK, Kivelevitch DN, et al. Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis. Drug Des Dev Ther. 2018;12:3879–83.CrossRefGoogle Scholar
  3. 3.
    AbbVie. Risankizumab (Skyrizi): Japanese prescribing information. 2019. http://www.pmda.go.jp/PmdaSearch/iyakuDetail/GeneralList/39994C9. Accessed 28 Mar 2019.
  4. 4.
    AbbVie. AbbVie announces first regulatory approval of SKYRIZI™ (risankizumab) for the treatment of plaque psoriasis, generalized pustular psoriasis and erythrodermic psoriasis and psoriatic arthritis in Japan [media release]. 26 Mar 2019. https://news.abbvie.com.
  5. 5.
    Abbvie. Health Canada approves SKYRIZI™ (risankizumab) for the treatment of moderate to severe plaque psoriasis [media release]. 18 Apr 2019. http://www.abbvie.ca/.
  6. 6.
    Abbvie. AbbVie expands immunology portfolio in the U.S. with FDA approval of SKYRIZI™ (risankizumab-rzaa) for moderate to severe plaque psoriasis [media release]. 23 Apr 2019. https://news.abbvie.com.
  7. 7.
    AbbVie. European Commission approves SKYRIZI™ (risankizumab) for the treatment of moderate to severe plaque psoriasis [media release]. 30 Apr 2019. https://news.abbvie.com.
  8. 8.
    AbbVie. SKYRIZI™ (risankizumab-rzaa) injection, for subcutaneous use: US prescribing information. 2019. https://www.rxabbvie.com/pdf/skyrizi_pi.pdf. Accessed 6 May 2019.
  9. 9.
    European Medicines Agency. Skyrizi (risankizumab): summary of product characteristics. 2019. http://ec.europa.eu/health/documents/community-register/2019/20190426144462/anx_144462_en.pdf. Accessed 6 May 2019.
  10. 10.
    AbbVie. AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds [media release]. 7 Mar 2016. http://www.boehringer-ingelheim.com.
  11. 11.
    Boehringer Ingelheim. Boehringer Ingelheim’s R&D in immunology. 2019. https://www.boehringer-ingelheim.com/immunology-inflammation/immunology/immunology-boehringer-ingelheim. Accessed 4 Apr 2019.
  12. 12.
    Suleiman A, Minocha M, Khatri A, et al. Population pharmacokinetics of risankizumab in healthy volunteers and subjects with moderate to severe plaque psoriasis: integrated analyses of phase I-III clinical trials. Clin Pharmacokinet. 2019.  https://doi.org/10.1007/s40262-019-00759-z.Google Scholar
  13. 13.
    Khatri A, Suleiman A, Polepally A, et al. Exposure-response relationships for efficacy and safety of risankizumab in patients with moderate to severe plaque psoriasis: integrated analyses of phase 2 and 3 clinical trials [poster no. 9908]. In: AAD Annual Meeting. 2019.Google Scholar
  14. 14.
    Khatri A, Cheng L, Camez A, et al. Lack of effect of 12-week treatment with risankizumab on the pharmacokinetics of cytochrome P450 probe substrates in patients with moderate to severe chronic plaque psoriasis. Clin Pharmacokinet. 2018.  https://doi.org/10.1007/s40262-018-0730-x.Google Scholar
  15. 15.
    Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–61.CrossRefGoogle Scholar
  16. 16.
    Foley P, Photowala H, Zhan T, et al. Durable efficacy of risankizumab compared with ustekinumab across subgroups of patients with moderate-to-severe plaque psoriasis: integrated analysis of two phase 3 trials [poster no. 9780]. In: AAD Annual Meeting. 2019.Google Scholar
  17. 17.
    Blauvelt A, Papp KA, Gooderham M, et al. Risankizumab efficacy/safety in moderate-to-severe plaque psoriasis: 16-week results from immhance [abstract no. P066]. Acta Derm Venereol. 2018;98(Suppl 219):30.Google Scholar
  18. 18.
    Langley R, Blauvelt A, Gooderham M, et al. Efficacy and safety of continuous Q12W risankizumab versus treatment withdrawal: results from the phase 3 IMMhance trial [poster no. 10093]. In: AAD Annual Meeting. 2019.Google Scholar
  19. 19.
    Reich K, Gooderham M, Thaçi D, et al. Efficacy and safety of continuous risankizumab or switching from adalimumab to risankizumab treatment in patients with moderate-to-severe plaque psoriasis: results from the phase 3 IMMvent trial [poster no. 10218]. In: AAD Annual Meeting. 2019.Google Scholar
  20. 20.
    Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376(16):1551–60.CrossRefGoogle Scholar
  21. 21.
    Mease PJ, Kellner H, Morita A, et al. Efficacy and safety of risankizumab, a selective IL-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial [abstract no. OP0307]. Ann Rheum Dis. 2018;77(Suppl. 2):200–1.Google Scholar
  22. 22.
    Mease PJ, Kellner H, Morita A, et al. Efficacy and safety results from a phase 2 trial of risankizumab, a selective IL-23p19 inhibitor, in patients with active psoriatic arthritis [abstract no. 2L]. In: ACR/ARHP Annual Meeting. 2017.Google Scholar
  23. 23.
    Papp KA, Gooderham M, Morita A, et al. Safety and efficacy results from the open label extension of a phase 2 trial of risankizumab, a selective IL-23p19 inhibitor in patients with active psoriatic arthritis [poster no. 8625]. In: AAD Annual Meeting. 2019.Google Scholar
  24. 24.
    Feagan BG, Sandborn WJ, D’Haens G, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017;389(10080):1699–709.CrossRefGoogle Scholar
  25. 25.
    Feagan BG, Panes J, Ferrante M, et al. Risankizumab in patients with moderate to severe Crohn’s disease: an open-label extension study. Lancet Gastroenterol Hepatol. 2018;3(10):671–80.CrossRefGoogle Scholar
  26. 26.
    Ferrante M, Panes J, Baert F, et al. Long-term safety and efficacy of risankizumab treatment in patients with Crohn’s disease: interim results of the ongoing phase 2 open-label extension study [abstract no. OP307]. United Eur Gastroenterol J. 2018;6(8 Suppl):A122–3.Google Scholar
  27. 27.
    Leonardi C, Bachelez H, Wu JJ, et al. Long-term safety of risankizumab in patients with moderate to severe psoriasis: analysis of pooled clinical trial data [poster no. 9891]. In: AAD Annual Meeting. 2019.Google Scholar
  28. 28.
    Strober B, Blauvelt A, Menter A, et al. Risankizumab treatment is associated with low and consistent infection rates over time in patients with moderate to severe psoriasis: analysis of pooled clinical trial data [poster no. 9876]. In: AAD Annual Meeting. 2019.Google Scholar
  29. 29.
    Reich K, Gordon KB, Tyring S, et al. Malignancy rates in patients with moderate to severe psoriasis during treatment with risankizumab: analysis of pooled clinical trial data [poster no. 9793]. In: AAD Annual Meeting. 2019.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations